Dashboard
1
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0.10%
- Poor long term growth as Operating profit has grown by an annual rate -260.06% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -12.53
- NO KEY NEGATIVE TRIGGERS
2
Risky -
3
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
EUR 455 Million ()
NA (Loss Making)
NA
0.00%
-0.06
-10.87%
1.11
Revenue and Profits:
Net Sales:
6 Million
(Quarterly Results - Mar 2016)
Net Profit:
0 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
10.13%
0%
10.13%
6 Months
2.61%
0%
2.61%
1 Year
-47.27%
0%
-47.27%
2 Years
-61.98%
0%
-61.98%
3 Years
-69.69%
0%
-69.69%
4 Years
-43.85%
0%
-43.85%
5 Years
-22.1%
0%
-22.1%
Formycon AG for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
9.80%
EBIT Growth (5y)
-260.06%
EBIT to Interest (avg)
-12.53
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.09
Sales to Capital Employed (avg)
0.27
Tax Ratio
14.40%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0.10%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.01
EV to EBIT
-10.61
EV to EBITDA
-27.20
EV to Capital Employed
1.01
EV to Sales
7.46
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-9.51%
ROE (Latest)
-10.87%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
69.70
77.70
-10.30%
Operating Profit (PBDIT) excl Other Income
-13.20
1.50
-980.00%
Interest
1.10
0.10
1,000.00%
Exceptional Items
-108.20
77.30
-239.97%
Consolidate Net Profit
-125.70
75.80
-265.83%
Operating Profit Margin (Excl OI)
-329.80%
-5.50%
-32.43%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -10.30% vs 82.82% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -265.83% vs 110.56% in Dec 2023
About Formycon AG 
Formycon AG
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






